DIRS.INFO The most relevant business & tech news

☆ Amgen scraps experimental weight loss pill, moves forward with injection
▼ + stars: | 2024-05-02 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Amgen on Thursday said it will stop developing its experimental weight loss pill and instead move forward with its injectable drug and other products in development for obesity. Amgen is developing an injectable obesity treatment called MariTide, which is an ongoing mid-stage trial in obese or overweight adults without diabetes. The drugmaker's oral drug, called AMG-786, is the second weight loss pill to be discontinued over the last year. Investors are laser-focused on Amgen's pipeline of experimental weight loss treatments. Amgen's injectable treatment also appears to help patients keep weight off after they stop taking it based on some clinical trial data.

Persons: Amgen, Eli Lilly, Jay Bradner, Novo Nordisk's Wegovy, Eli Lilly's Zepbound, Zepbound Organizations: Novo Nordisk, Pfizer, Novo Nordisk's Locations: Amgen, Thousand Oaks , California, MariTide, Novo

☆ Here are Monday's biggest analyst calls: Apple, Nvidia, Tesla, Meta, Amazon, Microsoft, Spotify, Ferrari & more
▼ + stars: | 2024-04-22 | by ( Michael Bloom | ) www.cnbc.com time to read: +7 min

Morgan Stanley reiterates Apple as overweight Morgan Stanley lowered its price target on the stock to $210 per share from $220 but says it's sticking with Apple. Bank of America reiterates Amazon as buy Bank of America said it's bullish heading into Amazon earnings next week. Bank of America reiterates Tesla as neutral Bank of America said it's sticking with its neutral rating on Tesla shares. Morgan Stanley upgrades Alcoa to equal weight from underweight Morgan Stanley said it sees a more balanced risk/reward for shares of Alcoa. Bank of America reiterates Apple as buy Bank of America says Apple is a top pick at the firm.

Persons: Goldman Sachs, Goldman, Morgan Stanley, it's, Piper Sandler, Piper, Apple, Q, Q revs, Papa, Stifel, Papa John's, Jefferies, Mizuho, JPMorgan, Raymond James downgrades, Raymond James, TD Cowen, BRBR, BMO downgrades, Tesla, Oppenheimer Organizations: Nvidia, NVIDIA, RBC, Apple, Microsoft, Meta, Bank of America, JPMorgan, Cisco, Deutsche Bank, Realty Trust, Deutsche, Brands, BMO, of America, Alcoa, Kymera Therapeutics, " Bank of America Locations: Singapore, Asia, Brazil

☆ Eli Lilly’s weight loss drug Zepbound shows promise as a sleep apnea treatment in late-stage trials
▼ + stars: | 2024-04-17 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. Eli Lilly on Wednesday said its highly popular weight loss drug Zepbound showed the potential to treat patients with the most common sleep-related breathing disorder in two late-stage clinical trials. Zepbound was more effective than a placebo at reducing the severity of obstructive sleep apnea, or OSA, in patients with obesity after a year, according to preliminary data from both trials. Eli Lilly previously announced that the FDA granted Zepbound "fast track designation" for patients with moderate-to-severe OSA and obesity. Zepbound has slipped into shortages since receiving approval in the U.S. for weight management in November.

Persons: Eli Lilly’s, Eli Lilly, Zepbound, Dr, Jeff Emmick, Eli Lilly's Organizations: U.S . Food, Drug Administration, FDA, OSA Locations: New York City, U.S

☆ A nutritionist shares her simple diet for optimal health—'I'm not trying to be the most creative person on Earth'
▼ + stars: | 2024-04-13 | by ( Renée Onque | ) www.cnbc.com time to read: +2 min

Carissa Galloway has 10 years of experience as a registered dietitian nutritionist and is a nutrition consultant and personal trainer for Premier Protein. Prior to her career as a nutritionist, Galloway was a sideline sports reporter. How this nutritionist eats for optimal healthWhen it comes to Galloway's diet, she aims to get three types of foods in every meal: 1. Protein Protein is "hugely important for muscle growth and repair," Galloway says. "For weight management, protein foods help you feel full and satisfied," she adds.

Persons: Carissa Galloway, Galloway, chia Organizations: Protein, CNBC, U.S . Department of Agriculture, Harvard Health Publishing Locations: Galloway, U.S

☆ Exclusive: Glen Tullman's startup Transcarent is raising $125 million in new funding at a $2.1 billion valuation
▼ + stars: | 2024-03-25 | by ( Rebecca Torrence | ) www.businessinsider.com time to read: +3 min

Read previewLivongo veteran Glen Tullman's latest venture, healthcare startup Trascarent, is raising a Series D round, Business Insider has learned. The sources said the round values Transcarent at about $2.1 billion. Related storiesIt's been a difficult fundraising environment for growth-stage healthcare startups — and that's reflected in Transcarent's latest fundraising push. Transcarent has raised $298 million to date, last grabbing $200 million in a January 2022 Series C round that boosted its valuation to $1.6 billion. Transcarent also acquired 98point6's virtual care platform in March 2023 to offer on-demand telehealth care.

Persons: —, Glen Tullman's, General Catalyst, Leslie Krigstein, Transcarent, Tullman, Teladoc, 98point6 Organizations: Service, General, Business, Catalyst, Human, Ally, Group, Alta Partners, Merck Global Health Innovation Fund, Jove Equity, Ventures, GreatPoint Ventures, Intermountain Healthcare, Rush University Medical, Soda Health Locations: Transcarent

☆ Amgen wants in on the booming weight loss drug market — and it's taking a different approach
▼ + stars: | 2024-03-24 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +9 min

Mario Tama | Getty ImagesAmgen is taking a new approach as it tries to stand out in a crowded field of drugmakers racing to develop the next blockbuster weight loss drug. It's too early to say how competitive Amgen will be in the budding weight loss drug space, which Novo Nordisk and Eli Lilly have so far dominated. Goldman Sachs also projects that between 10 million and 70 million Americans will be taking weight loss drugs by 2028. The sustained weight loss in Amgen's study appears to contrast with results seen in clinical trials on Zepbound and Wegovy. An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023.

Persons: Mario Tama, Eli Lilly, Goldman Sachs, Zepbound, Eli Lilly's, Amgen's MartiTide, Caroline Apovian, Apovian, Joe Buglewicz, MariTide, Holly Lofton, Eli Lilly’s, Brendan McDermid, Reuters Amgen's, William Blair, Matt Phipps, Phipps Organizations: Getty, Novo Nordisk, Pfizer, Viking Therapeutics, Therapeutics, Zealand Pharma, Boehringer, Center, Weight Management, Wellness, Brigham, Women's, Washington Post, NYU Langone Health, Reuters, William Blair & Company, CNBC Locations: Thousand Oaks , California, Oaks , California, Novo, New York City, U.S

☆ Oprah Winfrey tears up recounting her weight loss journey in primetime special
▼ + stars: | 2024-03-18 | by ( Megan Thomas | ) edition.cnn.com time to read: +3 min

CNN —It’s been nearly 13 years since “The Oprah Winfrey Show” came to an end, but for viewers of her weight loss special on Monday night, it likely felt like Winfrey’s talk show was back. “An Oprah Special: Shame, Blame and the Weight Loss Revolution” featured Winfrey doing what she proved for 25 seasons on “The Oprah Winfrey Show” she can do better than just about anyone else: bring people together and get them talking – and listening – to each other. Winfrey, too, shared the pain she has felt at times in her weight journey. “It’s not a matter of willpower.”The medical experts addressed potential side effects of weight loss medications and factors and risks that should be considered before taking it as part of a multiifaceted care plan. Winfrey spoke about her use of weight loss medication as one “tool” to manage her weight, combined with hiking, running, weight resistance training and eating a healthy diet.

Persons: CNN — It’s, Oprah Winfrey, ”, “, Winfrey, ” Winfrey, Scott Butsch, Amanda Velazquez, It’s, ” Butsch, “ It’s, Let’s Organizations: CNN, Obesity, Metabolic, Cleveland Clinic Locations: United States, Sinai, Los Angeles

☆ Oprah Takes on Weight Stigma in the Ozempic Era
▼ + stars: | 2024-03-18 | by ( Dani Blum | ) www.nytimes.com time to read: +1 min

Oprah Winfrey, a longtime figure in the national conversation about dieting and weight bias, devoted an hourlong prime-time special on Monday to the rise of weight loss drugs. Her goal, she said, was to “start releasing the stigma and the shame and the judgment” around weight and weight loss — starting with her own, she said. “For 25 years, making fun of my weight was national sport,” Ms. Winfrey said in the show, titled “An Oprah Special: Shame, Blame and the Weight Loss Revolution.”Shame has become a focal point in that conversation as new drugs like Ozempic and Mounjaro, which are widely used for weight loss, shift how people think about treating obesity. When Ms. Winfrey disclosed in December that she was taking a medication to manage her weight, she said she was “done with the shaming” that had followed her through decades of dieting. Many patients who start taking these medications say they have felt shamed for struggling with their weight, and then shamed for taking weight loss drugs, said Dr. Michelle Hauser, the obesity medicine director of the Stanford Lifestyle and Weight Management Center, who was not involved with the special.

Persons: Oprah Winfrey, Ms, Winfrey, Michelle Hauser Organizations: Stanford, Management

☆ Weight loss drug Wegovy is now approved for heart health — but that won't mean broad insurance coverage just yet
▼ + stars: | 2024-03-16 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +12 min

The blockbuster drug — one of a handful of weight loss treatments to skyrocket in popularity over the last year — is now approved in the U.S. for heart health, too. The spokesperson added that state Medicaid programs would be required to cover Wegovy for its new cardiovascular use. But Gremminger said the standard of care for the long-term use of weight loss drugs is "in flux." State employees will no longer have insurance coverage for GLP-1s when used for weight loss at the beginning of next month. Both drugmakers have launched programs to help patients, with or without commercial insurance coverage, afford their weight loss treatments.

Persons: Klesty, John Crable, Wegovy, Jaime Almandoz, Joe Buglewicz, Shawn Gremminger, Hartley, Gremminger, Dale Folwell, We've, Folwell, Phelan M, Eli Lilly, Ceci Connolly, Julie Stich Organizations: Reuters, Novo Nordisk, CNBC, Medicare, Services, FDA, CVS, Aetna, International Foundation of Employee, Drug Administration, University of Texas Southwestern Medical Center, Washington Post, Getty, National Alliance of Healthcare, Taft, Nordisk, Nordisk's Ozempic, GOP, Carolina, Republican Governors Association, AP, Alliance of Community Health, U.S . Health, IFEBP, BMI Locations: U.S, Novo, Dallas, North Carolina, Orlando , Florida

☆ Oprah has left WeightWatchers, sending stocks spiraling and spelling doom for the diet of our foremothers
▼ + stars: | 2024-02-29 | by ( Mia De Graaf | Rachel Hosie | ) www.businessinsider.com time to read: +7 min

Oprah Winfrey will not seek reelection to the board of WW International, known as WeightWatchers. It was a surprising time to jump on board — WeightWatchers had been shedding users, and its stock price was dwindling. AdvertisementDespite not naming the brand, there was an immediate spike in demand for GLP-1 medications — the popular new class of weight-loss drugs. That same day, WW added a weight-loss drug arm to its business, acquiring Sequence, a service that provides weight-loss drugs. AdvertisementLong-term, WW needs to find a new identityOver time, WW will benefit from being a purveyor of hard-to-access weight-loss drugs.

Persons: Oprah Winfrey, —, Oprah giveth, Oprah taketh, maven, Winfrey, — WeightWatchers, Axios, Oprah, Forbes, Craig, Alex Fuhrman, Winfrey's, We're, Atkins Organizations: WW International, Service, SEC, Guardian, People Magazine, MarketWatch, Mayo Clinic, Business, Smithsonian's National Museum of, CNBC, Slate Locations: GLP, WeightWatchers

☆ Thinking about taking new weight loss drugs? These are the big health risk decisions that will follow
▼ + stars: | 2024-02-28 | by ( Eric Rosenbaum | ) www.cnbc.com time to read: +6 min

In this article NOVO.B-DKLLYWWGWW Follow your favorite stocks CREATE FREE ACCOUNTAn injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. But will Americans trust the most iconic brand in the legacy weight-loss business to guide them into its future? "Big pharma was coming for weight loss, and if they didn't have a clinical angle, they would have run the risk of becoming an irrelevant company." "This is a new, incredibly powerful and effective class of pharmaceuticals that a lot of people will find help improve their health." watch nowRisks of overreliance on obesity drugs The risk is real that providers may use the medications and "forget about lifestyle," said John Batsis, an associate professor and nutrition expert at the University of North Carolina Chapel Hill's school of public health.

Persons: Eli Lilly’s, Brendan Mcdermid, Eli Lilly, —, Sima Sistani —, Sistani, Alex Fuhrman, Hallum, Fuhrman, Davidson, Linda Bolton Weiser, I've, Geoff Cook, Cook, John Batsis, Batsis Organizations: Reuters, Novo Nordisk, CNBC, Craig, pharma, University of North, University of North Carolina Chapel Locations: New York City, U.S, Herbalife, University of North Carolina

☆ A personal trainer lost 13 pounds in a month while eating Domino's pizza daily to prove you can lose weight and enjoy treats
▼ + stars: | 2024-02-20 | by ( Rachel Hosie | ) www.businessinsider.com time to read: +7 min

Read previewA personal trainer and college student lost over 13 pounds in a month while eating a Domino’s pizza every day, to prove that it’s possible to enjoy treats and lose fat as long as you’re in a calorie deficit . “Foods shouldn't be feared just because they've undergone some sort of processing,” Jayden Lee, 18, Lee told Business Insider. Typically, weight loss of one to two pounds a month on average is deemed safe. AdvertisementHowever, Lee doesn't recommend people try to follow his daily pizza diet to lose weight, and neither does Ludlam-Raine. “Occasional indulgence in foods like pizza is part of a balanced diet and can help prevent feelings of deprivation,” Ludlam-Raine said.

Persons: —, they've, Jayden Lee, Lee, dietitian Nichola Ludlam, Raine, Jayden Lee Lee, “, ”, ” Lee, Jordan, Lee isn’t, won’t, Lee doesn't, ” Ludlam, Domino's Organizations: Service, Business, USDA Locations: Portsmouth, UK

☆ Opinion: Ozempic and similar drugs mean nothing for patients who can’t access them
▼ + stars: | 2024-02-19 | by ( Opinion Jody Dushay | ) edition.cnn.com time to read: +6 min

We discussed that for many people, the most powerful tools for medical weight management are the glucagon like peptide 1 (GLP1) agonists. As of 2024, insurance, not body weight or BMI, has become the most important vital sign for doctors who see patients for medical weight management. They really did transform a fairly barren landscape of pharmacotherapeutic options for medical weight management that lasted several decades. Weight loss is on average about 15% with Wegovy and 22% with Zepbound, with super responders losing more than 25% of their body weight. By comparison, other medications that are FDA-approved for weight loss, including Qsymia and Contrave, are combinations of much older drugs.

Persons: Jody Dushay, MMSc, Beth, I’ve, Stanley, —, cravings Organizations: Medicine, Harvard Medical School, Beth Israel Deaconess Medical, CNN, Insurance, FDA, Medicare Locations: Boston, prediabetes

☆ Most employer health plans don't cover new blockbuster weight loss drugs, but that's going to change
▼ + stars: | 2024-02-16 | by ( Cheryl Winokur Munk | ) www.cnbc.com time to read: +10 min

Many U.S. companies are grappling with health insurance coverage issues for workers when it comes to GLP-1 drugs for weight loss. Still, many benefits experts say it's a matter of when, not if, more employers will cover GLP-1 drugs. Certainly, prescription volumes of GLP-1 weight loss drugs are soaring. Even though GLP-1 drugs are high-priced, they currently represent only 6.9% of annual claims, according to data from the International Foundation of Employee Benefit Plans. It's going to be harder and harder not to cover these drugs because the benefits seem to be so great."

Persons: Eli Lilly, there's, Julie Stich, Eli Lilly's, Greg Stancil, you've, Stancil, somebody's, James Wantuck, " Stich, Brian O'Connell, O'Connell, Wantuck, Krutika Amin, Amin Organizations: U.S, Nordisk, International Foundation of Employee, Novo Nordisk, Tufts Medical, Medicare, Healthy Aging, Scott Benefit Services, Employers, Accolade, BMI, International Foundation of, Medicaid — Locations: U.S, KFF, North Carolina, GLP, Novo

☆ What Ozempic Taught Me About Shame — and Willpower
▼ + stars: | 2024-02-15 | by ( Albert Fox Cahn | ) www.businessinsider.com time to read: +16 min

It will mean fundamentally reevaluating our conception of free will and human agency — and reckoning with our tortured relationship with shame. Many health plans have refused to cover GLP-1s for weight loss , citing limited approval from the Food and Drug Administration. I don't know when I first became overweight, but I remember the moment I was taught to be ashamed of it. They can stop the vicious feedback loop where our food choices and weight drive the shame that drives our food choices and weight. But no matter how heavy that burden was, one thing made it easier to bear: I wasn't weighed down by my shame.

Persons: I'd, They're, —, dieters, I've, Wayne LaPierre, David Vades Joseph, Mounjaro, …, you'd, would've, Kit Kat, they've, untangling, Stephen Spielberg's Organizations: National Rifle Association, NRA, Food and Drug Administration, New York City Marathon, Harvard Law School, GLP, BI Locations: York, Greenwich Village, darting, GLP

Eli Lilly rode soaring demand for diabetes and weight-loss treatments to a better-than-expected finish in 2023, and the drugmaker expects momentum to carry into the new year. Lilly said on Tuesday that revenue could climb as much as 22% this year, as star sellers like the diabetes drug Mounjaro and its new weight-loss counterpart, Zepbound, gain market share. Mounjaro sales jumped 65% to $2.21 billion in the fourth quarter compared with the third quarter. Doctors also prescribe that drug off-label for weight loss, which is one of the hottest areas of pharmaceutical sales. The share price for Indianapolis-based Eli Lilly and Co. has climbed over 400% since the start of the decade.

Persons: Eli Lilly, Lilly, Doctors, David Ricks, “, ”, FactSet, donanemab Organizations: Company, Revenue, Drug Administration, Indianapolis Locations: Mounjaro, North Carolina

☆ Tirzepatide: Weight loss drug helps significantly lower blood pressure in adults who are overweight or obese, study finds
▼ + stars: | 2024-02-05 | by ( Mira Cheng | ) edition.cnn.com time to read: +6 min

The participants had their blood pressure monitored for a day before beginning treatment and again after nine months of weekly tirzepatide injections. The results showed a significant decrease in the participants’ systolic blood pressure, the top number in blood pressure readings, which is a strong predictor of heart disease. It works similarly to semaglutide, the active compound in the weight loss drug Wegovy and its sister diabetes drug, Ozempic. Although there are effective blood pressure medications available, only about a quarter of people with hypertension have adequately controlled blood pressure, Hall said. He views the weight loss effect of the drug as a pleasant side effect that will make people more likely to take their medication.

Persons: —, Eli Lilly, ”, Harlan Krumholz, Michael E, Wegovy, it’s, Ania Jastreboff, Hall, Krumholz, tirzepatide, Dr, Sanjay Gupta, CNN’s Meg Tirrell Organizations: CNN, American Heart Association, Food and Drug Administration, Yale University, Department of Medicine, University of Mississippi Medical Center, Yale Obesity Research Center, CNN Health Locations: United States

☆ 'Botched' star Terry Dubrow calls Ozempic 'a miracle' but admits it takes 'all the joy of eating away'
▼ + stars: | 2024-01-22 | by ( Amanda Goh | ) www.businessinsider.com time to read: +2 min

"Botched" star and plastic surgeon Terry Dubrow told Page Six that he tried Ozempic. Dubrow called the weight-loss drug "a miracle" but admitted it took "all the joy of eating away." He said he wanted to see what it's like if you're not diabetic and "only have 10-15 pounds to lose." Advertisement"Botched" star Terry Dubrow says he tried Ozempic but gave it up because it took "all the joy of eating away." In a Page Six interview alongside costar Paul Nassif, the plastic surgeon admitted to giving the weight-loss drug a go because he was curious about its effects.

Persons: Terry Dubrow, Dubrow, —, Paul Nassif, Evan Real, Heather Dubrow — Organizations: Service, Page, Housewives, FDA Locations: Orange

☆ Your tax dollars are getting spent on weight-loss drugs like Ozempic, and the total is adding up
▼ + stars: | 2024-01-11 | by ( Juliana Kaplan | Ayelet Sheffey | ) www.businessinsider.com time to read: +7 min

AdvertisementConnecticut was quick to experience the impact of weight loss drugs on its economy last year. Politico reported in November that the state's employee health plan was set to spend $30 million on drugs like Ozempic and Wegovy. Comptroller Sean Scanlon told BI that that was up from $8 million in 2020. Connecticut began testing out a method to offer those seeking weight loss drugs access to a program with online tools for weight management. In North Carolina, the State Health Plan has put a moratorium on new users of GLP-1 drugs for weight loss.

Persons: Sean Scanlon, Scanlon, it's, Dale Folwell, Folwell, Shelby Livingston, Eli Lilly, that'll, Nik Modi Organizations: Service, Business, Bloomberg, Medicaid, Politico, BI, State, North, State Health, Novo Nordisk, Wall Street, University of Texas System, UT, RBC Capital Markets Locations: Connecticut, Wegovy, . Connecticut, North Carolina, Novo, Netherlands, United States

☆ The CEO of an A16z-backed healthcare startup is pitching a better way to save money on obesity care
▼ + stars: | 2023-12-29 | by ( ) www.businessinsider.com time to read: +8 min

Boyarsky Pratt said about 35% of Knownwell's patients come for primary care, while the rest see the company's providers for their metabolic health. They can prescribe GLP-1 drugs, but they're just one tool the company uses to treat obesity, Boyarsky Pratt said. It's also planning to partner with more health systems to help them expand access to weight care. It partners with one large system in Massachusetts now, but Boyarsky Pratt declined to disclose which one. "The data shows that the earlier patients get into a comprehensive treatment, the better for the long-term course of the disease," Boyarsky Pratt said.

Persons: —, Brooke Boyarsky Pratt, Andreessen Horowitz, Boyarsky Pratt, Knownwell, Angela Fitch, Berkadia, Fitch, Needham, Boyarsky Platt, they'd, Michael Siluk, It's Organizations: Service, Business, GLP, BMI, Medicare, Obesity Medicine Association . Obesity Medicine, University of Pennsylvania, Harvard Business School, Berkshire Hathaway, Obesity Medicine Association, Weight, Flare Capital Partners, Staff, Getty, American Academy of Pediatrics Locations: Boston, GLP, Massachusetts, Knownwell, Needham , Massachusetts, telehealth

☆ Oprah's flip on weight loss drugs is a sign of what's to come for the 'Ozempic trade' in 2024
▼ + stars: | 2023-12-25 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +10 min

Lilly's Zepbound recently entered the weight loss market, and is off to a strong start. But what's ahead for the weight loss trade in 2024? Beyond weight loss One of 2023's most pivotal events in the space was Novo Nordisk's release of top line results from its Select trial in August . In 2023, the exuberance around weight loss drugs roiled markets in many unexpected ways. The affected companies have also been very vocal in addressing how they plan to coexist with these weight loss products.

Persons: Oprah Winfrey, Eli Lilly, they've, Lilly's, Lilly's Zepbound, Andy Acker, Janus Henderson's, Lilly, Novo, FactSet, Acker, Janus, Buzz, Gregory Renza, Renza, Goldman Sachs, Chris Shibutani, Mike Kratky, Kratky, Dexcom, Leerink, Winfrey, I've, Winfrey's, Michael Bloom Organizations: Novo Nordisk, Wall Street, Wall, RBC Capital, Pfizer, Structure Therapeutics, AstraZeneca, Leerink, Nestle, Oprah Daily, Winfrey, International Locations: Friday's, Eccogene, MedTech, 3Q23

☆ Eli Lilly vs. Novo Nordisk: The pros deliver their verdict on the viral weight-loss stocks
▼ + stars: | 2023-12-06 | by ( Amala Balakrishner | ) www.cnbc.com time to read: +4 min

It has been quite a year for both Eli Lilly and Novo Nordisk given the boom in weight-loss drugs. Shares in Eli Lilly are up around 60% year-to-date, while its Danish counterpart Novo Nordisk has seen a gain of around 50%. At present, both Eli Lilly and Novo Nordisk offer weight loss treatments. Novo Nordisk Novo Nordisk's Wegovy recently made headlines for reducing the risk of heart attacks and strokes by 20% in adults with heart disease and obesity. Aside from Eli Lilly and Novo Nordisk, Pfizer , Johnson & Johnson and AstraZeneca are also developing weight-loss drugs.

Persons: Eli Lilly, Stocks, Rahul Ghosh, Rowe Price, TRP's Ghosh, Eli Lilly's, Ghosh, FactSet, Lilly, Novo Nordisk Novo Nordisk's Wegovy, Elizabeth Field, Squawk, What's, it's, Michael Bloom Organizations: Novo Nordisk, Nordisk, CNBC Pro, U.S . Food, Administration, pharma, Novo Nordisk Novo Nordisk's, Heart Association Scientific, Citi, Pfizer, Johnson, AstraZeneca, Barclays Locations: Danish, U.S, Novo

☆ How to use calories and macros to lose weight, explained as simply as possible by a fat loss coach and a dietitian
▼ + stars: | 2023-12-02 | by ( Rachel Hosie | ) www.businessinsider.com time to read: +7 min

To lose weight you need to be in a calorie deficit: that's the most important factor, experts said. AdvertisementIf you want to lose weight, it can be confusing to know where to start. But do you need to count calories to lose weight? A balanced meal incudes carbs, protein, fat, and fiber. "But if someone has a healthy relationship with food, they really shouldn't have to be more precise than tracking calories, protein and fiber."

Persons: —, dietitian Alix Turoff, Turoff, Jordan Syatt, Joff Lee, Syatt, There's Organizations: Service

☆ Maker of Wegovy, Ozempic showers money on U.S. obesity doctors
▼ + stars: | 2023-12-01 | by ( ) www.reuters.com time to read: +23 min

Novo spent at least $25.8 million over the past decade on U.S. medical professionals to promote its two obesity drugs, Wegovy and Saxenda, the analysis found. Jastreboff has also worked on clinical trials of obesity drugs for Eli Lilly, which markets a Wegovy competitor. Some doctors said Novo’s payments exemplify how the flood of industry money can dominate decision-making about care and coverage. Government pharmacy officer Solaru said her agency concluded that the new obesity drugs could be cost-effective by preventing other weight-related diseases and boosting workplace productivity. In January, the personnel office told its health plans they must cover at least one GLP-1 obesity drug for 8 million workers, retirees and family members.

Persons: Lee Kaplan, Kaplan, ”, gastroenterologist, He’s, Novo, Donna Ryan, Ryan, “, ” Kaplan, ” Novo, Robert Lustig, “ I’m, Lustig, They’re, Ania, ” Jastreboff, Jastreboff, Eli Lilly, Lilly’s Zepbound, Lilly, ” Lilly, Novo’s, Ayana, Sanders, Arthur Kellermann, ” Kellermann, mouthpieces, ’ ”, “ I'm, Jamy Ard, Ard, Dele, ” Solaru, ” Ryan, Scott Kahan, Kahan, Solaru, Christine Gallagher, Wegovy, Rebekah Carl, Carl, Jen Wexler, gaunt, Wexler Organizations: Novo Nordisk, Dartmouth, Nutrition Institute, Massachusetts General Hospital, Harvard Medical School, Reuters, Cambridge, Obesity Society, U.S ., Management, Reuters . Pharmaceutical, ”, U.S, United, National Health Service, University of California, U.S . Food, Drug Administration, Doctors, Wegovy’s, BMI, Yale University’s Center, Weight Management, Wall Street, American Medical Association, Rutgers University’s School of Public Health, Affordable, . Pharmaceutical, Companies, Uniformed Services University of Health Sciences, Wake Forest University, Wake Forest Baptist Health Weight Management, Obesity, Pennington Biomedical Research, U.S . National Institutes of Health, Personnel Management, Coalition, STOP, George Washington University, Novo Locations: CAMBRIDGE, Massachusetts, Boston, U.S, Novo, Danish, United States, Louisiana, San Francisco, Wegovy, Pennington, Baton Rouge , Louisiana, Government, New Columbia , Pennsylvania, Florida

☆ Suspected fake Ozempic causes hypoglycemia in 11 in Lebanon
▼ + stars: | 2023-11-28 | by ( Patrick Wingrove | ) www.reuters.com time to read: +4 min

Three of the people who took the suspected fake Ozempic did so to control their diabetes, while four took it for weight management, Karam said. People with diabetes need to closely manage their blood sugar, which can be done with a variety of medicines including Ozempic. Lebanon's Ministry of Public Health issued two recalls related to Ozempic in January 2023, according to its website. Karam said Ozempic is neither purchased nor provided by the Ministry of Public Health. Several people have been hospitalized in Austria for hypoglycemia after taking potentially fake versions of Ozempic.

Persons: Rita Karam, Eli Lilly's, Novo's, Karam, Ozempic, Patrick Wingrove, Caroline Humer, Bill Berkrot Organizations: Lebanese Ministry of Public Health, Lebanon's Ministry of Public Health, Novo Nordisk, World Obesity, Obesity, International Diabetes Federation, Ministry of Public Health, Reuters, Thomson Locations: Lebanon, Germany, Egypt, Russia, United States, Novo, Britain, Belgium, Austria

Search resuls for: "Weight Management"

25 mentions found